摘要:
A novel process for preparing the compounds of the formula I where: n is 0, 1 or 2; R1, R2 are C1-C6-alkyl; R3, R4, R5 are hydrogen or C1-C6-alkyl, or R4 and R5 together form a bond; R6 is Cl, Br, which comprises a synthesis sequence starting from 1,2-dialkylbenzenes of the formula II with subsequent halogenation to give 3,6-dihalo-1,2-dialkylbenzenes, haloalkylation to give benzyl bromides, oxidation to give benzaldehydes, oximation, reaction with alkenes to give isoxazoles, conversion into thioethers and, if appropriate, oxidation to give sulfenyl or sulfonyl derivatives of the formula I.
摘要翻译:一种制备式I化合物的新方法,其中n为0,1或2; R 1,R 2为C 1 -C 6 - 烷基; R 3,R 4,R 5为氢或C 1 -C 6烷基,或者R 4和R 5一起形成 R 6是Cl,Br,其包含从式II的1,2-二烷基苯开始的合成序列,随后卤化以得到3,6-二卤代-1,2-二烷基苯,卤代烷基化得到苄基溴,氧化得到 苯甲醛,肟化,与烯烃的反应得到异恶唑,转化成硫醚,如果合适,氧化得到式I的磺酰基或磺酰基衍生物。
摘要:
A process for synthesizing leflunomide from 5-methylisoxazole-4-carboxylic acid and 4-trifluoromethylaniline is provided in which the carboxylic acid group of 5-methylisoxazole-4-carboxylic acid is chlorinated, forming 5-methylisoxazole-4-carboxylic acid chloride. The acid chloride is then reacted without intermediate distillation with 4-trifluoromethylaniline in the presence of an alkali metal or alkaline-earth metal bicarbonate acid scavenger.
摘要:
A novel process for preparing the compounds of the formula I where: n is 0, 1 or 2; R1, R2 are C1-C6-alkyl; R3, R4, R5 are hydrogen or C1-C6-alkyl, or R4 and R5 together form a bond; R6 is Cl, Br, which comprises a synthesis sequence starting from 1,2-dialkylbenzenes of the formula II with subsequent halogenation to give 3,6-dihalo-1,2-dialkylbenzenes, haloalkylation to give benzyl bromides, oxidation to give benzaldehydes, oximation, reaction with alkenes to give isoxazoles, conversion into thioethers and, if appropriate, oxidation to give sulfenyl or sulfonyl derivatives of the formula I.
摘要翻译:一种制备式I化合物的新方法,其中n为0,1或2; R 1,R 2为C 1 -C 6 - 烷基; R 3,R 4,R 5为氢或C 1 -C 6烷基,或者R 4和R 5一起形成 R 6是Cl,Br,其包含从式II的1,2-二烷基苯开始的合成序列,随后卤化以得到3,6-二卤代-1,2-二烷基苯,卤代烷基化得到苄基溴,氧化得到 苯甲醛,肟化,与烯烃的反应得到异恶唑,转化成硫醚,如果合适,氧化得到式I的磺酰基或磺酰基衍生物。
摘要:
A novel process for preparing the compounds of the formula I where: n is 0, 1 or 2; R1, R2 are C1-C6-alkyl; R3, R4, R5 are hydrogen or C1-C6-alkyl, or R4 and R5 together form a bond; R6 is Cl, Br, which comprises a synthesis sequence starting from 1,2-dialkylbenzenes of the formula II with subsequent halogenation to give 3,6-dihalo-1,2-dialkylbenzenes, haloalkylation to give benzyl bromides, oxidation to give benzaldehydes, oximation, reaction with alkenes to give isoxazoles, conversion into thioethers and, if appropriate, oxidation to give sulfenyl or sulfonyl derivatives of the formula I.
摘要翻译:一种制备式I化合物的新方法,其中n为0,1或2; R 1,R 2为C 1 -C 6 - 烷基; R 3,R 4,R 5, 或者R 4和R 5一起形成键; R 6是Cl,Br,其包含从式II的1,2-二烷基苯开始的合成序列,随后 卤化得到3,6-二卤代-1,2-二烷基苯,卤代烷基化得到苄基溴,氧化得到苯甲醛,肟化,与烯烃反应得到异恶唑,转化成硫醚,如果合适,氧化得到亚硫酰基或磺酰基衍生物 的式I。
摘要:
New leflunomide Form III is disclosed, along with processes for preparing it. The present invention also provides an economic process for preparing leflunomide Form II and a process for preparing leflunomide Form I from leflunomide Form III. Pharmaceutical compositions and dosage forms containing the new form and methods of using them for the treatment of rheumatoid arthritis are also disclosed.
摘要:
The invention relates to a crystal modification of the compound of the formula I and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type 11 diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.